Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Aripiprazole-lauroxil | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Aripiprazole-lauroxil | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Aripiprazole-lauroxil | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Aripiprazole-lauroxil | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Aripiprazole-lauroxil | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Aripiprazole-lauroxil | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Aripiprazole-lauroxil | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Aripiprazole-lauroxil | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Aripiprazole-lauroxil | hsa04080 | Neuroactive ligand-receptor interaction | 2.84E-03 | 7 | P28472, P21453, Q9H228, Q01726, P41968, P21730, P07550 | GABRB3, S1PR1, EDG8, MC1R, MC3R, C5AR1, ADRB2 | More | | Aripiprazole-lauroxil | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Aripiprazole-lauroxil | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Aripiprazole-lauroxil | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Aripiprazole-lauroxil | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.7 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P48382 | RFX5 | DNA-binding protein RFX5 | 0.826 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.743 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 |
| Aripiprazole-lauroxil | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | Q05397 | PTK2 | Focal adhesion kinase 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.919 | Q05397 | PTK2 | Focal adhesion kinase 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.849 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P13612 | ITGA4 | Integrin alpha-4 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.732 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.862 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P13612 | ITGA4 | Integrin alpha-4 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.768 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q05397 | PTK2 | Focal adhesion kinase 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.898 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P13612 | ITGA4 | Integrin alpha-4 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.814 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.922 | P13612 | ITGA4 | Integrin alpha-4 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.818 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P13612 | ITGA4 | Integrin alpha-4 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.729 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.778 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P13612 | ITGA4 | Integrin alpha-4 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.772 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 | P13612 | ITGA4 | Integrin alpha-4 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.772 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Aripiprazole-lauroxil | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Aripiprazole-lauroxil | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Aripiprazole-lauroxil | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Aripiprazole-lauroxil | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Aripiprazole-lauroxil | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Aripiprazole-lauroxil | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Aripiprazole-lauroxil | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Aripiprazole-lauroxil | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Aripiprazole-lauroxil | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Aripiprazole-lauroxil | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Aripiprazole-lauroxil | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Aripiprazole-lauroxil | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Aripiprazole-lauroxil | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Aripiprazole-lauroxil | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Aripiprazole-lauroxil | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Aripiprazole-lauroxil | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Aripiprazole-lauroxil | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | | Aripiprazole-lauroxil | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Aripiprazole-lauroxil | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Aripiprazole-lauroxil | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Aripiprazole-lauroxil | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Aripiprazole-lauroxil | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Aripiprazole | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Aripiprazole | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | | Aripiprazole | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Aripiprazole | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Aripiprazole | hsa00190 | Oxidative phosphorylation | 4.38E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Aripiprazole | hsa00220 | Arginine biosynthesis | 2.20E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Aripiprazole | hsa00310 | Lysine degradation | 1.53E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Aripiprazole | hsa00500 | Starch and sucrose metabolism | 3.18E-08 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Aripiprazole | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | | Aripiprazole | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Aripiprazole | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 6.96E-04 | 1 | Q9NY97 | B3GNT2 | More | | Aripiprazole | hsa00562 | Inositol phosphate metabolism | 2.54E-03 | 4 | P27987, Q13572, Q96PE3, P42338 | ITPKB, ITPK1, INPP4A, PIK3CB | More | | Aripiprazole | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Aripiprazole | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Aripiprazole | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Aripiprazole | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | Aripiprazole | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Aripiprazole | hsa00730 | Thiamine metabolism | 2.43E-06 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Aripiprazole | hsa00770 | Pantothenate and CoA biosynthesis | 9.52E-06 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Aripiprazole | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Aripiprazole | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.94E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Aripiprazole | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Aripiprazole | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Aripiprazole | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Aripiprazole | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Aripiprazole | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Aripiprazole | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | Aripiprazole | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Aripiprazole | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Aripiprazole | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Aripiprazole | hsa02010 | ABC transporters | 1.66E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Aripiprazole | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Aripiprazole | hsa03010 | Ribosome | 7.34E-03 | 6 | P62753, P62829, P62888, P61927, P61513, P36578 | RPS6, RPL23, RPL30, RPL37, RPL37A, RPL4 | More | | Aripiprazole | hsa03013 | RNA transport | 2.29E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Aripiprazole | hsa03020 | RNA polymerase | 2.25E-03 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Aripiprazole | hsa03022 | Basal transcription factors | 2.68E-04 | 3 | O00268, Q5H9L4, Q15544 | TAF4, TAF7L, TAF11 | More | | Aripiprazole | hsa03040 | Spliceosome | 1.45E-06 | 14 | Q14562, O43143, O60508, Q99633, P08579, P26368, Q13595, Q07955, Q01130, Q13243, Q9UMS4, P11142, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS5, PRPF19, HSPA8, PPIH, ASCC3L1 | More | | Aripiprazole | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Aripiprazole | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Aripiprazole | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Aripiprazole | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Aripiprazole | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Aripiprazole | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04012 | ErbB signaling pathway | 1.72E-02 | 4 | Q13153, P16333, P19174, P01106 | PAK1, NCK1, PLCG1, MYC | More | | Aripiprazole | hsa04014 | Ras signaling pathway | 1.38E-02 | 6 | P42338, P49767, P08069, P0DP23, P63218, P50151 | PIK3CB, VEGFC, IGF1R, CALM1, GNG5, GNG10 | More | | Aripiprazole | hsa04015 | Rap1 signaling pathway | 4.21E-03 | 7 | P20827, P49767, P08069, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, IGF1R, ACTG1, F2R, CALM1, PRKCA | More | | Aripiprazole | hsa04020 | Calcium signaling pathway | 2.42E-07 | 10 | P27987, P21796, Q16566, P17252, P30679, O15399, P25116, P0DP23, P23634, P49767 | ITPKB, VDAC1, CAMK4, PRKCA, GNA15, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | Aripiprazole | hsa04024 | cAMP signaling pathway | 3.22E-04 | 7 | P42338, P0DP23, P23634, Q16566, O15399, P25116, Q13153 | PIK3CB, CALM1, ATP2B4, CAMK4, GRIN2D, F2R, PAK1 | More | | Aripiprazole | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Aripiprazole | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 9.53E-04 | 7 | P09341, P25024, P02775, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, PPBP, XCL1, XCL2, IL10RA, IL2RB | More | | Aripiprazole | hsa04062 | Chemokine signaling pathway | 8.88E-05 | 12 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ARRB1, ITK, GSK3B | More | | Aripiprazole | hsa04064 | NF-kappa B signaling pathway | 2.00E-07 | 19 | P10415, Q13489, P51617, O00463, Q13546, P14778, P01375, P29965, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, Q06643 | BCL2, BIRC3, IRAK1, TRAF5, RIPK1, IL1R1, TNF, CD40LG, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, LTB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.744 | P51684 | CCR6 | C-C chemokine receptor type 6 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.84 | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | P51684 | CCR6 | C-C chemokine receptor type 6 | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | 0.722 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.945 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.868 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P17252 | PRKCA | Protein kinase C alpha type | P29965 | CD40LG | CD40 ligand | 0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P17252 | PRKCA | Protein kinase C alpha type | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.769 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.869 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.768 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P17252 | PRKCA | Protein kinase C alpha type | Q8WV28 | BLNK | B-cell linker protein | 0.838 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P17252 | PRKCA | Protein kinase C alpha type | Q13315 | ATM | Serine-protein kinase ATM | 0.739 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 | P51684 | CCR6 | C-C chemokine receptor type 6 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.712 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 |
| Aripiprazole | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04070 | Phosphatidylinositol signaling system | 2.22E-06 | 10 | P19174, P0DP23, Q14643, P42338, P23743, Q96PE3, O14732, Q13572, P27987, P17252 | PLCG1, CALM1, ITPR1, PIK3CB, DGKA, INPP4A, IMPA2, ITPK1, ITPKB, PRKCA | More | | Aripiprazole | hsa04071 | Sphingolipid signaling pathway | 1.20E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | Aripiprazole | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Aripiprazole | hsa04114 | Oocyte meiosis | 1.43E-03 | 6 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0, P08069 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | | Aripiprazole | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Aripiprazole | hsa04140 | Autophagy - animal | 6.54E-02 | 6 | P08069, P22694, Q14643, P10415, Q9H1Y0, Q04759 | IGF1R, PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Aripiprazole | hsa04141 | Protein processing in endoplasmic reticulum | 3.07E-02 | 5 | P30101, P60604, P11142, P08238, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SSR3 | More | | Aripiprazole | hsa04145 | Phagosome | 2.11E-06 | 13 | O75015, P63261, Q15080, P14598, Q13509, P68371, Q13488, P05164, P78380, O60603, P35443, P27824, P13765 | FCGR3B, ACTG1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, OLR1, TLR2, THBS4, CANX, HLA-DOB | More | | Aripiprazole | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04151 | PI3K-Akt signaling pathway | 4.50E-02 | 9 | P25116, P49767, Q13362, P62873, P16144, O60603, P01568, P10415, P17252 | F2R, VEGFC, PPP2R5C, GNB1, ITGB4, TLR2, IFNA21, BCL2, PRKCA | More | | Aripiprazole | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Aripiprazole | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04213 | Longevity regulating pathway - multiple species | 1.66E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Aripiprazole | hsa04217 | Necroptosis | 6.35E-06 | 16 | P01375, P01568, P48023, Q13489, Q9NQC7, P42224, Q14765, P07900, P15104, P01584, Q6FI13, Q99878, P10415, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, CYLD, STAT1, STAT4, HSP90AA1, GLUL, IL1B, H2AC18; H2AC19, H2AC14, BCL2, CHMP4B, CHMP2A, PPID | More | | Aripiprazole | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.45E-04 | 10 | P09493, P07550, P22694, P18848, Q13362, Q16537, P0DP23, P17252, P10415, P20020 | TPM1, ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | Aripiprazole | hsa04310 | Wnt signaling pathway | 1.79E-02 | 2 | P17612, P67870 | PRKACA, CSNK2B | More | | Aripiprazole | hsa04340 | Hedgehog signaling pathway | 2.36E-03 | 3 | P49841, P17612, P22694 | GSK3B, PRKACA, PRKACB | More | | Aripiprazole | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Aripiprazole | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Aripiprazole | hsa04371 | Apelin signaling pathway | 4.42E-04 | 8 | P62873, P63218, P50151, Q13370, Q14814, Q13485, Q16566, P0DP23 | GNB1, GNG5, GNG10, PDE3B, MEF2D, SMAD4, CAMK4, CALM1 | More | | Aripiprazole | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Aripiprazole | hsa04390 | Hippo signaling pathway | 1.36E-04 | 7 | P63261, P84022, Q13485, O15105, Q9UJU2, O43623, Q13489 | ACTG1, SMAD3, SMAD4, SMAD7, LEF1, SNAI2, BIRC3 | More | | Aripiprazole | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | Aripiprazole | hsa04510 | Focal adhesion | 9.88E-03 | 7 | Q15942, P17252, Q13489, P10415, P08069, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, IGF1R, VEGFC, ACTG1 | More | | Aripiprazole | hsa04520 | Adherens junction | 2.26E-03 | 5 | Q13485, Q9UJU2, O43623, P08069, P63261 | SMAD4, LEF1, SNAI2, IGF1R, ACTG1 | More | | Aripiprazole | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | | Aripiprazole | hsa04540 | Gap junction | 1.53E-03 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Aripiprazole | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, Q02750, P08069, Q86SE9 | BMPR2, MAP2K1, IGF1R, PCGF5 | More | | Aripiprazole | hsa04610 | Complement and coagulation cascades | 1.27E-10 | 2 | P00734, P0C0L4 | F2, C4A | More | | Aripiprazole | hsa04611 | Platelet activation | 2.12E-02 | 2 | Q9Y490, P17612 | TLN1, PRKACA | More | | Aripiprazole | hsa04612 | Antigen processing and presentation | 1.03E-06 | 10 | P13765, P48382, P01730, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.7 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P48382 | RFX5 | DNA-binding protein RFX5 | 0.826 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.743 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 |
| Aripiprazole | hsa04613 | Neutrophil extracellular trap formation | 1.82E-06 | 20 | P19174, P17252, P11215, O60603, P08246, Q13547, Q92769, P04908, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, P21462, P60709, O43315, Q16539 | PLCG1, PRKCA, ITGAM, TLR2, ELA2, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, ACTB, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | P51684 | CCR6 | C-C chemokine receptor type 6 | P17252 | PRKCA | Protein kinase C alpha type | 0.738 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P11215 | ITGAM | Integrin alpha-M | -0.913 | P17252 | PRKCA | Protein kinase C alpha type | O60603 | TLR2 | Toll-like receptor 2 | -0.716 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | P17252 | PRKCA | Protein kinase C alpha type | P08246 | ELA2 | Neutrophil elastase | -0.735 | P51684 | CCR6 | C-C chemokine receptor type 6 | P08246 | ELA2 | Neutrophil elastase | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13547 | HDAC1 | Histone deacetylase 1 | 0.7 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q92769 | HDAC2 | Histone deacetylase 2 | 0.702 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P04908 | H2AC4; H2AC8 | Histone H2A type 1-B/E | 0.734 | P17252 | PRKCA | Protein kinase C alpha type | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.83 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.86 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.737 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q93077 | HIST1H2AC | Histone H2A type 1-C | -0.742 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | -0.833 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P51684 | CCR6 | C-C chemokine receptor type 6 | P33778 | H2BC3 | Histone H2B type 1-B | 0.704 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | -0.833 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | O60814 | H2BC12 | Histone H2B type 1-K | -0.732 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.913 | P17252 | PRKCA | Protein kinase C alpha type | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.783 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P17252 | PRKCA | Protein kinase C alpha type | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.821 | P51684 | CCR6 | C-C chemokine receptor type 6 | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.713 | P17252 | PRKCA | Protein kinase C alpha type | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.836 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.803 | P17252 | PRKCA | Protein kinase C alpha type | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.731 | P51684 | CCR6 | C-C chemokine receptor type 6 | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.7 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P60709 | ACTB | Actin, cytoplasmic 1 | 0.726 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O43315 | AQP9 | Aquaporin-9 | -0.764 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 |
| Aripiprazole | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Aripiprazole | hsa04621 | NOD-like receptor signaling pathway | 2.92E-02 | 3 | P01584, P07900, P43490 | IL1B, HSP90AA1, PBEF1 | More | | Aripiprazole | hsa04625 | C-type lectin receptor signaling pathway | 8.18E-03 | 5 | Q9ULY5, Q13153, P20749, P01375, Q16539 | CLEC4E, PAK1, BCL3, TNF, MAPK14 | More | | Aripiprazole | hsa04640 | Hematopoietic cell lineage | 7.06E-05 | 12 | P13612, P14778, P27930, P15144, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Aripiprazole | hsa04650 | Natural killer cell mediated cytotoxicity | 2.24E-13 | 16 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13153, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, PAK1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | Q05397 | PTK2 | Focal adhesion kinase 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.919 | Q05397 | PTK2 | Focal adhesion kinase 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.849 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P13612 | ITGA4 | Integrin alpha-4 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.732 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.862 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P13612 | ITGA4 | Integrin alpha-4 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.768 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q05397 | PTK2 | Focal adhesion kinase 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.898 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P13612 | ITGA4 | Integrin alpha-4 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.814 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.922 | P13612 | ITGA4 | Integrin alpha-4 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.818 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P13612 | ITGA4 | Integrin alpha-4 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.729 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.778 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P13612 | ITGA4 | Integrin alpha-4 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.772 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 | P13612 | ITGA4 | Integrin alpha-4 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.772 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Aripiprazole | hsa04657 | IL-17 signaling pathway | 1.31E-06 | 10 | P07900, O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Aripiprazole | hsa04658 | Th1 and Th2 cell differentiation | 3.49E-12 | 14 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P07305 | H1-0 | Histone H1.0 | Q04759 | PRKCQ | Protein kinase C theta type | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P13612 | ITGA4 | Integrin alpha-4 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.729 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P13612 | ITGA4 | Integrin alpha-4 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.768 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P13612 | ITGA4 | Integrin alpha-4 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.85 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P13612 | ITGA4 | Integrin alpha-4 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.732 | P07305 | H1-0 | Histone H1.0 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.716 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.904 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P13612 | ITGA4 | Integrin alpha-4 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.764 | P07305 | H1-0 | Histone H1.0 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.772 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P13612 | ITGA4 | Integrin alpha-4 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.822 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.842 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07305 | H1-0 | Histone H1.0 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.859 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.789 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | P13612 | ITGA4 | Integrin alpha-4 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.78 |
| Aripiprazole | hsa04659 | Th17 cell differentiation | 6.60E-09 | 18 | P25963, Q04759, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P07305 | H1-0 | Histone H1.0 | Q04759 | PRKCQ | Protein kinase C theta type | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P07305 | H1-0 | Histone H1.0 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.716 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.842 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07305 | H1-0 | Histone H1.0 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.859 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.713 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P07305 | H1-0 | Histone H1.0 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.772 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.869 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 |
| Aripiprazole | hsa04660 | T cell receptor signaling pathway | 4.60E-10 | 15 | P01375, Q9UDY8, Q04759, O95267, Q08881, Q13153, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, PAK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.925 | P13612 | ITGA4 | Integrin alpha-4 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.834 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 1 | P13612 | ITGA4 | Integrin alpha-4 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P13612 | ITGA4 | Integrin alpha-4 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.729 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P13612 | ITGA4 | Integrin alpha-4 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.768 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P13612 | ITGA4 | Integrin alpha-4 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.85 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | P13612 | ITGA4 | Integrin alpha-4 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.7 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.811 | P13612 | ITGA4 | Integrin alpha-4 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.83 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P13612 | ITGA4 | Integrin alpha-4 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.732 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Aripiprazole | hsa04664 | Fc epsilon RI signaling pathway | 2.20E-03 | 6 | P01375, Q16539, P42338, Q9UQC2, P07948, P09917 | TNF, MAPK14, PIK3CB, GAB2, LYN, ALOX5 | More | | Aripiprazole | hsa04666 | Fc gamma R-mediated phagocytosis | 2.25E-03 | 7 | P07948, P42338, P23528, P49006, P06396, P14598, P17252 | LYN, PIK3CB, CFL1, MARCKSL1, GSN, NCF1, PRKCA | More | | Aripiprazole | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | | Aripiprazole | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Aripiprazole | hsa04710 | Circadian rhythm | 4.40E-02 | 1 | O15516 | CLOCK | More | | Aripiprazole | hsa04713 | Circadian entrainment | 6.27E-04 | 7 | O15399, P0DP23, P17252, P62873, P63218, P50151, Q14643 | GRIN2D, CALM1, PRKCA, GNB1, GNG5, GNG10, ITPR1 | More | | Aripiprazole | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Aripiprazole | hsa04720 | Long-term potentiation | 2.04E-07 | 8 | P17252, Q16566, P16298, P0DP23, P51812, O15399, Q02750, Q14643 | PRKCA, CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1, ITPR1 | More | | Aripiprazole | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Aripiprazole | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | Aripiprazole | hsa04724 | Glutamatergic synapse | 4.10E-02 | 3 | O15399, P63218, P50151 | GRIN2D, GNG5, GNG10 | More | | Aripiprazole | hsa04725 | Cholinergic synapse | 3.17E-04 | 8 | Q14643, P17252, P62873, P63218, P50151, Q16566, P42338, P10415 | ITPR1, PRKCA, GNB1, GNG5, GNG10, CAMK4, PIK3CB, BCL2 | More | | Aripiprazole | hsa04726 | Serotonergic synapse | 1.52E-02 | 4 | P63218, P50151, P33260, P09917 | GNG5, GNG10, CYP2C18, ALOX5 | More | | Aripiprazole | hsa04728 | Dopaminergic synapse | 3.80E-04 | 12 | Q14643, P17252, P14416, P62873, P63218, P50151, P49841, Q16539, P49407, Q13362, P0DP23, O00327 | ITPR1, PRKCA, DRD2, GNB1, GNG5, GNG10, GSK3B, MAPK14, ARRB1, PPP2R5C, CALM1, ARNTL | More | | Aripiprazole | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Aripiprazole | hsa04742 | Taste transduction | 7.70E-04 | 2 | P30939, P17612 | HTR1F, PRKACA | More | | Aripiprazole | hsa04744 | Phototransduction | 8.61E-05 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Aripiprazole | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Aripiprazole | hsa04912 | GnRH signaling pathway | 3.85E-03 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Aripiprazole | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | | Aripiprazole | hsa04914 | Progesterone-mediated oocyte maturation | 1.91E-03 | 5 | P08069, Q17RY0, Q9Y6D9, P51812, Q02750 | IGF1R, CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Aripiprazole | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Aripiprazole | hsa04919 | Thyroid hormone signaling pathway | 6.82E-04 | 9 | P49841, P19174, P42224, P22694, P60709, Q13547, O60244, Q9NVC6, P01106 | GSK3B, PLCG1, STAT1, PRKACB, ACTB, HDAC1, MED14, MED17, MYC | More | | Aripiprazole | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Aripiprazole | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | Aripiprazole | hsa04924 | Renin secretion | 7.38E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | Aripiprazole | hsa04925 | Aldosterone synthesis and secretion | 2.55E-05 | 6 | Q14643, P0DP23, P17252, Q16566, P20020, P23634 | ITPR1, CALM1, PRKCA, CAMK4, ATP2B1, ATP2B4 | More | | Aripiprazole | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 8 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15 | More | | Aripiprazole | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Aripiprazole | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Aripiprazole | hsa04932 | Non-alcoholic fatty liver disease | 2.43E-04 | 8 | P01375, P49841, P48023, P01584, P12074, O15239, Q16718, O14521 | TNF, GSK3B, FASLG, IL1B, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Aripiprazole | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 6.24E-05 | 7 | P84022, Q13485, P42224, P10415, Q12778, P49767, P17252 | SMAD3, SMAD4, STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | | Aripiprazole | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Aripiprazole | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.40E-02 | 1 | O00141 | SGK | More | | Aripiprazole | hsa04964 | Proximal tubule bicarbonate reclamation | 2.17E-03 | 1 | P00918 | CA2 | More | | Aripiprazole | hsa04966 | Collecting duct acid secretion | 3.24E-07 | 4 | Q13488, P02730, P00918, Q9Y666 | TCIRG1, SLC4A1, CA2, SLC12A7 | More | | Aripiprazole | hsa04970 | Salivary secretion | 4.63E-05 | 8 | P07550, P22694, Q14643, P20020, P23634, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1, CAMP | More | | Aripiprazole | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Aripiprazole | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Aripiprazole | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Aripiprazole | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Aripiprazole | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Aripiprazole | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | | Aripiprazole | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | Aripiprazole | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Aripiprazole | hsa05017 | Spinocerebellar ataxia | 5.94E-03 | 4 | Q8TB72, O15399, P42338, P21796 | PUM2, GRIN2D, PIK3CB, VDAC1 | More | | Aripiprazole | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | Aripiprazole | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | | Aripiprazole | hsa05031 | Amphetamine addiction | 1.61E-03 | 7 | O15399, P0DP23, Q16566, P22694, P18848, P17252, Q13547 | GRIN2D, CALM1, CAMK4, PRKACB, ATF4, PRKCA, HDAC1 | More | | Aripiprazole | hsa05032 | Morphine addiction | 1.90E-02 | 4 | P62873, P63218, Q13370, P43250 | GNB1, GNG5, PDE3B, GRK6 | More | | Aripiprazole | hsa05034 | Alcoholism | 2.83E-06 | 11 | O15399, Q16566, Q13547, P0DP23, P62873, P63218, P50151, Q93077, P62807, O60814, P68431 | GRIN2D, CAMK4, HDAC1, CALM1, GNB1, GNG5, GNG10, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Aripiprazole | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | Aripiprazole | hsa05110 | Vibrio cholerae infection | 2.11E-03 | 2 | Q99437, P17612 | ATP6V0B, PRKACA | More | | Aripiprazole | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.61E-04 | 6 | Q16539, Q13153, P09341, P25024, P25025, P07948 | MAPK14, PAK1, CXCL1, CXCR1, CXCR2, LYN | More | | Aripiprazole | hsa05131 | Shigellosis | 2.27E-02 | 8 | P68431, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | Aripiprazole | hsa05132 | Salmonella infection | 7.94E-07 | 14 | P51617, P25963, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, NFKBIA, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Aripiprazole | hsa05133 | Pertussis | 2.94E-06 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Aripiprazole | hsa05134 | Legionellosis | 4.28E-02 | 3 | P11215, P11142, P19875 | ITGAM, HSPA8, CXCL2 | More | | Aripiprazole | hsa05135 | Yersinia infection | 6.38E-03 | 9 | Q05397, P51812, P13612, P06239, Q16539, Q02750, P01375, P49841, Q96JJ3 | PTK2, RPS6KA3, ITGA4, LCK, MAPK14, MAP2K1, TNF, GSK3B, ELMO2 | More | | Aripiprazole | hsa05140 | Leishmaniasis | 1.54E-06 | 12 | P13612, O75015, P14598, P42224, P13765, O60603, P01375, P29350, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, TNF, PTPN6, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Aripiprazole | hsa05143 | African trypanosomiasis | 1.11E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Aripiprazole | hsa05144 | Malaria | 5.21E-07 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Aripiprazole | hsa05145 | Toxoplasmosis | 1.02E-03 | 7 | P25963, P10415, Q13489, P42224, P13765, O60603, P29965 | NFKBIA, BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | Aripiprazole | hsa05146 | Amoebiasis | 7.98E-06 | 11 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Aripiprazole | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Aripiprazole | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | Aripiprazole | hsa05160 | Hepatitis C | 1.16E-03 | 6 | P52630, P60033, Q9NZJ5, P49841, P01375, P48023 | STAT2, CD81, EIF2AK3, GSK3B, TNF, FASLG | More | | Aripiprazole | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Aripiprazole | hsa05163 | Human cytomegalovirus infection | 2.54E-05 | 13 | P42338, P01375, P63218, P50151, Q14643, P0DP23, P49841, P14778, P25025, Q16539, P04637, O00463, P30101 | PIK3CB, TNF, GNG5, GNG10, ITPR1, CALM1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5, PDIA3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.757 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.814 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.718 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P0DP23 | CALM1 | Calmodulin-1 | -0.764 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.857 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.788 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.712 |
| Aripiprazole | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | Aripiprazole | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.79E-04 | 13 | P01568, P42224, P42338, P62873, P63218, P50151, P19875, P19174, Q14643, P07948, P01106, P0DP23, Q9UJU2 | IFNA21, STAT1, PIK3CB, GNB1, GNG5, GNG10, CXCL2, PLCG1, ITPR1, LYN, MYC, CALM1, LEF1 | More | | Aripiprazole | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | Aripiprazole | hsa05169 | Epstein-Barr virus infection | 5.23E-05 | 19 | P13765, P01106, Q13547, Q92769, P04637, Q13546, O00463, P10415, P07948, P30101, Q13761, P24522, O75293, P42224, O60603, P51617, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, HDAC2, TP53, RIPK1, TRAF5, BCL2, LYN, PDIA3, RUNX3, GADD45A, GADD45B, STAT1, TLR2, IRAK1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P01106 | MYC | Myc proto-oncogene protein | 0.834 | P06239 | LCK | Tyrosine-protein kinase Lck | P01106 | MYC | Myc proto-oncogene protein | 0.719 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13547 | HDAC1 | Histone deacetylase 1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13547 | HDAC1 | Histone deacetylase 1 | 0.811 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q92769 | HDAC2 | Histone deacetylase 2 | 0.702 | P51684 | CCR6 | C-C chemokine receptor type 6 | P04637 | TP53 | Cellular tumor antigen p53 | 0.728 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.868 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P51684 | CCR6 | C-C chemokine receptor type 6 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.84 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.851 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.789 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P51684 | CCR6 | C-C chemokine receptor type 6 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.712 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.787 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | P51684 | CCR6 | C-C chemokine receptor type 6 | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | 0.722 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P51684 | CCR6 | C-C chemokine receptor type 6 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.753 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 |
| Aripiprazole | hsa05170 | Human immunodeficiency virus 1 infection | 1.21E-05 | 17 | P42338, P62873, P63218, P50151, P0DP23, P17252, Q13546, P30101, Q14643, P01568, P51617, O60603, Q13315, P23528, P09693, P10415, Q9Y6Q5 | PIK3CB, GNB1, GNG5, GNG10, CALM1, PRKCA, RIPK1, PDIA3, ITPR1, IFNA21, IRAK1, TLR2, ATM, CFL1, CD3G, BCL2, AP1M2 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.757 | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.814 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.718 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P0DP23 | CALM1 | Calmodulin-1 | -0.764 | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | P51684 | CCR6 | C-C chemokine receptor type 6 | P0DP23 | CALM1 | Calmodulin-1 | -0.734 | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | P51684 | CCR6 | C-C chemokine receptor type 6 | P17252 | PRKCA | Protein kinase C alpha type | 0.738 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.868 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.712 | P17252 | PRKCA | Protein kinase C alpha type | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | 0.786 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | 0.81 | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | P51684 | CCR6 | C-C chemokine receptor type 6 | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | 0.722 | P17252 | PRKCA | Protein kinase C alpha type | O60603 | TLR2 | Toll-like receptor 2 | -0.716 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | P17252 | PRKCA | Protein kinase C alpha type | Q13315 | ATM | Serine-protein kinase ATM | 0.739 | O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | P23528 | CFL1 | Cofilin-1 | 0.715 | P51684 | CCR6 | C-C chemokine receptor type 6 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.753 | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | P51684 | CCR6 | C-C chemokine receptor type 6 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.84 | P17252 | PRKCA | Protein kinase C alpha type | Q9Y6Q5 | AP1M2 | AP-1 complex subunit mu-2 | -0.829 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6Q5 | AP1M2 | AP-1 complex subunit mu-2 | -0.86 |
| Aripiprazole | hsa05171 | Coronavirus disease - COVID-19 | 3.18E-03 | 7 | P01584, P62753, P36578, P62888, P61927, P61513, P62829 | IL1B, RPS6, RPL4, RPL30, RPL37, RPL37A, RPL23 | More | | Aripiprazole | hsa05200 | Pathways in cancer | 2.51E-04 | 23 | P08238, P42224, P19174, P01106, Q9UJU2, P17252, P43246, Q13485, P20585, Q13547, P14923, P10415, Q13489, P49767, Q12778, P25116, P62873, P63218, P78417, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, PLCG1, MYC, LEF1, PRKCA, MSH2, SMAD4, MSH3, HDAC1, JUP, BCL2, BIRC3, VEGFC, FOXO1, F2R, GNB1, GNG5, GSTO1, GADD45B, CALM1, IFNA21, IL2RB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.869 | P17252 | PRKCA | Protein kinase C alpha type | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P01106 | MYC | Myc proto-oncogene protein | 0.834 | P17252 | PRKCA | Protein kinase C alpha type | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.881 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.724 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P20585 | MSH3 | DNA mismatch repair protein Msh3 | 0.731 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13547 | HDAC1 | Histone deacetylase 1 | 0.7 | P17252 | PRKCA | Protein kinase C alpha type | P14923 | JUP | Junction plakoglobin | 0.761 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P17252 | PRKCA | Protein kinase C alpha type | P49767 | VEGFC | Vascular endothelial growth factor C | 0.719 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | P17252 | PRKCA | Protein kinase C alpha type | Q12778 | FOXO1 | Forkhead box protein O1 | 0.863 | P17252 | PRKCA | Protein kinase C alpha type | P25116 | F2R | Proteinase-activated receptor 1 | 0.857 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.725 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.756 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.787 | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.744 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.842 |
| Aripiprazole | hsa05202 | Transcriptional misregulation in cancer | 1.52E-03 | 13 | Q13315, P14780, P27930, Q15744, Q16548, Q13077, P08069, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | ATM, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Aripiprazole | hsa05203 | Viral carcinogenesis | 5.30E-03 | 7 | P06746, P29083, Q13547, Q15283, P12814, P62807, O60814 | POLB, GTF2E1, HDAC1, RASA2, ACTN1, HIST1H2BC, H2BC12 | More | | Aripiprazole | hsa05204 | Chemical carcinogenesis | 1.61E-03 | 3 | P78417, P11712, P33260 | GSTO1, CYP2C9, CYP2C18 | More | | Aripiprazole | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | Aripiprazole | hsa05206 | MicroRNAs in cancer | 3.17E-02 | 6 | P30304, P09493, P01106, Q9Y4H2, Q13547, P19174 | CDC25A, TPM1, MYC, IRS2, HDAC1, PLCG1 | More | | Aripiprazole | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Aripiprazole | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | | Aripiprazole | hsa05212 | Pancreatic cancer | 4.21E-03 | 3 | P37173, P84022, Q13485 | TGFBR2, SMAD3, SMAD4 | More | | Aripiprazole | hsa05214 | Glioma | 1.13E-06 | 9 | P08069, P0DP23, Q16566, P17252, P42338, P04637, P19174, P24522, O75293 | IGF1R, CALM1, CAMK4, PRKCA, PIK3CB, TP53, PLCG1, GADD45A, GADD45B | More | | Aripiprazole | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Aripiprazole | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Aripiprazole | hsa05218 | Melanoma | 9.63E-04 | 4 | P08069, P09619, Q9GZP0, Q02750 | IGF1R, PDGFRB, PDGFD, MAP2K1 | More | | Aripiprazole | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Aripiprazole | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | Aripiprazole | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Aripiprazole | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | Aripiprazole | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Aripiprazole | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Aripiprazole | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | Aripiprazole | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.32E-03 | 9 | O95267, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Aripiprazole | hsa05310 | Asthma | 1.03E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Aripiprazole | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Aripiprazole | hsa05321 | Inflammatory bowel disease | 1.17E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Aripiprazole | hsa05322 | Systemic lupus erythematosus | 1.33E-06 | 11 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P62807, O60814, P68431, P12814 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Aripiprazole | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | Aripiprazole | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | Aripiprazole | hsa05332 | Graft-versus-host disease | 7.43E-06 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Aripiprazole | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Aripiprazole | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 6.71E-04 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Aripiprazole | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Aripiprazole | hsa05415 | Diabetic cardiomyopathy | 1.58E-03 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B | More | | Aripiprazole | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | Aripiprazole | hsa05418 | Fluid shear stress and atherosclerosis | 1.42E-06 | 13 | Q16539, Q14145, P78417, P10599, P14780, P01375, P63261, P04637, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, KEAP1, GSTO1, TXN, MMP9, TNF, ACTG1, TP53, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |